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Technical Note
High-Resolution MRI of Deep-Seated
Atherosclerotic Arteries Using Motexafin
Gadolinium
Chris Brushett, MS,1,2 Bensheng Qiu, PhD,1,3 Ergin Atalar, PhD,1,4 and
Xiaoming Yang, MD, PhD1,3*
Purpose: To evaluate the potential of using motexafin gad-
olinium (MGd) to characterize atherosclerotic plaques of
deep-seated arteries with MRI.
Materials and Methods: We exposed vascular endothelial
cells (EC) and smooth muscle cells (SMC) in vitro to varying
concentrations of MGd. The fluorescence properties of MGd
were then exploited using confocal microscopy to image
exposed cells. For an in vivo validation study, we performed
surface coil–based and intravascular coil–based high-res-
olution MRI of the iliac arteries and the abdominal aorta of
three atherosclerotic Yucatan pigs. Subsequently, MGd en-
hancement of the target vessel walls was quantitatively
evaluated and MR images were correlated with histology of
the target vessels.
Results: The in vitro study confirmed the intracellularization
of MGd in both cell types and determined the optimum MGd
dosage of 0.004 mmol/kg that produced the sufficiently high
intracellular fluorescent intensity. The in vivo study showed a
steady increase of MGd enhancement to approximately 25%
at three hours postinjection of MGd. MRI showed areas of
strong enhancement along the lumen boundary, which cor-
responded to fibrous tissue seen in histology.
Conclusion: This study provides initial evidence that MGd
may enhance MR vessel wall imaging for the characteriza-
tion of plaque in deep-seated arteries.
Key Words: atherosclerotic cardiovascular disease; mo-
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ATHEROSCLEROTIC CARDIOVASCULAR DISEASE is
still the leading cause of death in developed countries.
Atherosclerosis refers to the buildup of fatty deposits or
“plaque” in the innermost lining of the arterial wall.
Atherosclerotic plaque causes hardening of the artery
and narrowing of the vessel lumen, which can result in
the obstruction of blood flow and the reduction of oxy-
gen supply to the important tissues and organs of the
body. Current diagnostic techniques, such as conven-
tional X-ray angiography, focus on determining the de-
gree of stenosis in arteries, but it is now understood
that the composition and shape of the plaque, and not
the degree of stenosis, are the best indicators of future
acute events (1–3). A large lipid core with a thin or
ruptured fibrous cap is thought to indicate “vulnerable”
plaque with an elevated risk of thrombosis. To diagnose
a plaque as vulnerable, the plaque composition, rather
than plaque burden, must be identified. Previous works
using MR contrast agents to discriminate between
plaque components in the surface-seated arteries, pri-
marily the carotid arteries, have shown an increased
contrast between plaque components, such as fibrous
tissue and lipid (1–4).
However, it is a challenging task to generate high-
resolution MRI of atherosclerotic plaques in the deep-
seated arteries, such as the iliac arteries, the renal
arteries, and the aorta, due to insufficient MR signal-
to-noise ratios (SNRs) when using the body coil or sur-
face coils. Motexafin gadolinium (MGd; Pharmacyclics
Inc.), a gadolinium texaphyrin analog, is primarily de-
signed as an intracellularly localized anticancer agent
(5). MGd selectively accumulates in metabolically active
tissues, such as tumors. In addition, MGd can produce
red fluorescence when stimulated by blue light, and,
thus, can be tracked under fluorescence microscopy
(5,6). Because MGd contains gadolinium, it can also
function as a T1 MR contrast agent. These characteris-
tics of MGd encouraged us to evaluate MGd for high-
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resolution MRI of atherosclerotic plaques, which are
also metabolically active tissues, similar to tumors.
Currently, no studies have been performed investigat-
ing the in vitro localization of MGd within the vascular
cells involved in atherosclerosis. The potential of MGd
to provide plaque-specific contrast enhancement for
vulnerable plaque diagnosis of atherosclerotic disease
is also unknown.
The objectives of the present study were to: 1) evalu-
ate, in vitro, the intracellular properties of MGd, spe-
cific to atherosclerotic plaques, by confirming the inter-
nalization of MGd by vascular endothelial cells (EC) and
smooth muscle cells (SMC); and 2) investigate, in vivo,
the potential of using MGd as an MR T1 contrast agent
to discriminate between tissues in the atherosclerotic




MGd is an expanded porphyrin (texaphyrin) that con-
tains bound gadolinium within its macrocyclic core.
Texaphyrin molecules are known to be attracted to met-
abolically active cells, such as tumor cells, and there-
fore have strong potential in tumor imaging (5,7). The
mechanisms of cell uptake of MGd are not clear, but
considered as the effects of microenvironmental factors
present in cells such as low pH and hypoxia (8). The
fluorescent properties of MGd allow it to be imaged
under a confocal microscope, with fluorescence at 740
nm when excited at 470 nm.
In Vitro Study
The in vitro study included two cell groups: 1) the first
group to confirm intracellularization of MGd in vascular
ECs and SMCs; and 2) the second group to determine
the optimum concentration of MGd for subsequent in
vivo animal study.
In the first cell group, human ECs and SMCs (Cam-
brex Bio Science Walkersville, Inc., Walkersville, MD,
USA) were cultured in a six-well plate. 0.1 mL of 2 mM
MGd was added to 3 mL of basal media in each well. The
cells were cultured with 70 M MGd and the cell culture
medium (provided by the manufacturer) in a 37°C in-
cubator for 24 hours. Then, the cells were washed five
times with phosphate-buffered saline to remove all
MGd not bound to the membrane or internalized. The
cells were then allowed to culture in cell culture me-
dium for an additional 24 hours. After detaching the
cells from each other by 0.5 mL trypsin (25%) per well,
the cells from each well were collected in a centrifuge
tube. Nonexposed control cells were prepared in a sim-
ilar manner. Subsequently, cells were centrifuged,
scraped from each of the four tubes, and then fixed in
formalin on microscope slides for confocal microscopy
imaging.
The cells were imaged with a Zeiss LSM 410 confocal
microscope using a 470  10 nm excitation band-pass
filter with a 700-nm emission long-pass (far-red) filter,
and a power of 63 mW/cm2. Because MGd has an
emission wavelength (700 nm) at which mammalian
cells do not autofluoresce, all fluorescent signal de-
tected on the confocal microscope with the 700-nm
long-pass filter comes from the presence of MGd. A
standard black and white microscope image was also
taken and fluorescence images were displayed in
pseudocolor over the black and white images to show
the cellular location of the MGd.
The second cell group was used to determine the
optimum MGd dosage for subsequent in vivo animal
study. Additional ECs and SMCs were subcultured and
transferred to other six-well plates. The cells in each
well were exposed to solutions of 0, 5, 10, 25, 50, and
100 M MGd, respectively, for 24 hours. They were
washed, incubated, and extracted with the same
method described above. In each of cell groups, five
cells were randomly selected and imaged with the con-
focal microscope. Signal intensity was averaged over
the volume of the cells to obtain a measure of fluores-
cence, which was subsequently plotted against MGd
concentration. The MGd concentration at which the
increase fluorescent intensity became negligible was
considered the optimum MGd concentration. This con-
centration was used to determine dosages for the sub-




In vivo MRI studies were performed on three athero-
genic Yucatan pigs (approximately 65 kg). The pigs were
subjected to injury of the iliac arteries by balloon denu-
dation followed by a high-cholesterol diet (Research Di-
ets, Inc., New Brunswick, NJ, USA) for 18–24 months.
In addition to essential nutrients, vitamins, and salts,
the atherogenic diet contains 4% cholesterol, 14% beef
tallow, and 1% hog bile extract in daily amounts of
1000 g (9). All animals were treated according to the
“Principles of Laboratory Animal Care” of the National
Society for Medical Research and the “Guide for the
Care and Use of Laboratory Animals” (10). The Animal
Care and Use Committee at our institution approved
the experimental protocol.
Surface Coil–Based MRI
Under general anesthesia, the first and second Yucatan
pigs were placed in the 1.5T GE MR scanner. Dual 3-
and 5-inch surface coils were placed on the abdomen
and lower back, respectively. Two-dimensional time-of-
flight (TOF) MR angiography was performed to obtain
scout images to localize stenotic areas in the iliac arter-
ies distal to the aortic bifurcation and in the lower
abdominal aorta. Then, transverse images covering 3
cm of the iliac artery starting at the aortic bifurcation
were obtained using high-resolution MRI.
MR images were acquired with a double inversion-
recovery, fast spin-echo (FSE), black blood, electrocar-
diograph (ECG)-gated pulse sequence using breath-
holds in several locations along the 3-cm-long iliac
arteries. The imaging parameters were as follows: TI 
280 or 400 msec, TE  4.7 msec, heart rate (HR)  80
bpm, TR  1 heartbeat (750 msec), field of view
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(FOV)  30 cm, matrix size  256  256, echo train
length (ETL)  10, number of excitations (NEX)  2 or 6,
slice thickness  2 mm, and scan time  30 seconds.
This was a modified version of the imaging protocol
used by Wasserman et al (4).
With pig 1, we compared MR contrast enhancements
between MGd and gadopentetate dimeglumine (Magne-
vist®, Berlex Laboratories, Inc., Montville, NJ, USA).
After baseline images were taken, 11-mL Magnevist (0.1
mmol/kg) was intravenously administered via an ear
vein using a digital injector at the injection flow rate of
5 mL/second and flushed with 20-mL saline. Contrast-
enhanced imaging of the iliac artery was obtained in the
same locations as preinjection, at 5, 15, 30, 45, 60, 90,
115, and 120 minutes postinjection. Following this pro-
cedure, the pig was given a one-week break to allow for
complete washout of Magnevist. Subsequently, the ex-
act imaging of the iliac artery at the same level as im-
aged above was repeated using 25 mL of 2 mM MGd
(0.001 mmol/kg), which enabled us to achieve the same
dose of gadolinium as that of 11-mL Magnevist (0.1
mmol/kg) we used above.
With pig 2, we tested the ability to use surface coil–
based MRI with intravenous administration of MGd at
the optimized MGd dosage (0.004 mmol/kg, as estab-
lished from the in vitro study). We performed high-
resolution MRI of the iliac artery wall using the same
imaging protocol as used above, but the FOV was de-
creased to 18 cm for improved resolution and the NEX
was increased to 6 to compensate for lost SNR. In ad-
dition, the scan was extended to capture images at 150
minutes and 180 minutes postinjection.
Intravascular MRI
In the third Yucatan pig, we attempted to validate the
feasibility of performing intravascular high-resolution
MRI of the aortic plaques with MGd enhancement.
Through a surgical cutdown, a 7-F introducer was in-
serted into the left carotid artery, through which a cus-
tom 0.0032-inch MRI-guidewire (MRIG) (11,12) was po-
sitioned into the lower abdominal aorta under X-ray
guidance. The pig was then transferred to the 1.5T GE
scanner and high-resolution imaging was performed
using the intravascular MRIG and a 5-inch surface coil
placed on the abdomen. FSE, black-blood, ECG-gated
scans were prescribed in cross-section to the lower ab-
dominal aorta. The following MRI parameters were
used: TI  260 msec, TE  11.5 msec, HR  90 bpm,
TR  1 RR (670 msec), FOV  10 cm, matrix size 
256  192, ETL  10, NEX  10, slice thickness  2
mm, and scan time  130 seconds. The MRIG was
operated in receive-mode only. After baseline imaging,
68 mL of 5 mM MGd (0.004 mmol/kg) was injected at a
flow rate of 5 mL/second. Images were taken up to three
hours postcontrast.
Image Analysis
Using the surface coil–based MR images, MGd en-
hancement of the iliac artery wall was measured. Three
imaging slices of each artery were examined before and
up to two to three hours postinjection. For each image,
a series of 30 points were chosen randomly within the
vessel wall. These were averaged and normalized for all
three slices to achieve an average MR amplitude. Sub-
sequently, the amplitude was plotted for each agent
and for each time point to show how contrast enhance-
ment developed.
Histology
Once MRI was completed, the pig was euthanized with
a dose of 100 mg/kg of pentobarbital, and the imaged
tissues from the bilateral iliac arteries and the lower
abdominal aorta were harvested. The specimens were
embedded in paraffin, cut into 5-m slices on a cross-
sectional view, and stained with hematoxylin and eosin
(H&E) stain for microscopy examination.
RESULTS
In Vitro Study
Fluorescence was detected in exposed cells and was
contained within the cellular membrane, as shown in
Fig. 1. Confocal imaging showed internalization of MGd
in both ECs and SMCs. MGd was shown to accumulate
in the cytoplasm and was retained there for longer than
24 hours. Figure 2 shows fluorescence signal intensity
plotted against concentration for confocal microscopy
imaging. Near-maximal intensity was achieved with a
50 M concentration of MGd. This concentration cor-
Figure 1. Confocal microscope images with MGd fluorescence
overlaid in red pseudocolor. a: Endothelial cell after exposure
to 50 M MGd. b: Unexposed endothelial cell. c: Smooth mus-
cle cell after exposure to 50 M MGd.
Figure 2. Average fluorescence intensity plotted against MGd
concentration for EC and SMC. The paired histogram for each
concentration was similar in shape and showed nearly maxi-
mal intensity at 50 M concentration. au  arbitrary unit.
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responded to the manufacturer-recommended maxi-
mum dose of 0.004 mmol/kg MGd, which was selected
as our optimum concentration of MGd for the subse-
quent in vivo animal experiments. We achieved the op-
timal concentration of 0.004 mmol/kg MGd by estimat-
ing an amount of 5 liters of blood in the 65-kg pigs we
used. From there we converted the 0.004 mmol/kg dose
into a blood concentration of about 50 M ([0.004
mmol/kg]  [65 kg]/[5 liters]  0.052 mmol/liter 
50 M).
In Vivo Study
Since the vessels are small and deep inside the body,
the surface coil MR images suffer from low SNR. Al-
though this is the case, the effect of the contrast en-
hancements to the images could be visualized and
quantified. Contrast enhancement with Magnevist de-
veloped rapidly to a maximum of 37% by five minutes,
and then quickly began to decrease due to washout
from the blood stream. MGd exhibited a different be-
havior: enhancement increased steadily over the entire
three-hour period of imaging. An increased average sig-
nal enhancement of approximately 25% was seen at
three hours postinjection of MGd (Fig. 3). Wall thicken-
ing with nonuniform enhancement was visualized with
the enhancement being greatest close to the lumen
(Fig. 4).
With intravascular MR vessel wall imaging using the
MRIG, image SNR increased significantly and thus we
were able to reduce the FOV to 10 cm from 18 cm.
Contrast enhancement in the atherosclerotic aortic wall
was seen to occur again in a very nonuniform manner.
Vessel wall thickening became more clear two hours
after intravenous injection of MGd compared to the
preinjection image. Areas of strong enhancement were
seen along the lumen boundary, which corresponded to
the fibrous tissue seen in histology (Fig. 5). Histological
examination confirmed the presence of extensive wall
thickening due to complicated plaques.
DISCUSSION
MR vessel wall imaging of deep-seated arteries has been
a difficult task due to the low SNR when performing MRI
of these vessels with a surface or body coil. To overcome
this problem, we attempted to apply two different tech-
niques, including: 1) an intracellular MR contrast
agent, MGd, to specifically characterize different com-
ponents of the atherosclerotic plaques, and 2) an intra-
vascular MRIG to generate high-SNR MR vessel wall
imaging.
This study has confirmed the in vitro internalization
of MGd by both vascular endothelial and SMC using
confocal microscopy. MGd was shown to accumulate in
the cytoplasm of EC and SMC, and was retained there
for longer than 24 hours. These findings are similar to
Figure 5. (Left column) Intravascular 1.5T MR images of the
atherosclerotic aorta using the 0.032-inch MRIG before and
after intravenous administration of MGd. From top to bottom:
pre-, 30 minutes, 60 minutes, and 120 minutes post-MGd
injection. The fibrous cap (arrow) is outlined by MGd at 120
minutes. Scale bar  5 mm. (Right column) A corresponding
histology image of the aorta. The arrow indicates the fibrous
cap (H&E stain, 1.25). [Color figure can be viewed in the
online issue, which is available at www.interscience.wiley.
com.]
Figure 3. Average MR signal enhancement of the target vessel
wall over a two- to three-hour period for the two contrast
agents, presenting a sharp contrast enhancement with Mag-
nevist and a slow contrast enhancement for MGd (curve ob-
tained by combining the results of the MR signal intensities
from pigs 1 and 2).
Figure 4. Surface coil–based MR images of the iliac artery of a
pig, before (a) and three hours post-MGd injection (b). Uneven
enhancement of the artery wall (arrow) was seen with MGd.
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those found by Woodburn (6) with tumor cells (7),
which indicate that MGd can be taken up by not only
tumor cells but also vascular cells. These results may
indicate that under in vivo conditions, MGd should
localize into fibrous tissue and healthy vessel wall tis-
sue, which contain endothelial and SMC. Lipid pools
have few of these cells while necrotic cores are noncel-
lular; therefore, both should have low MGd concentra-
tions at equilibrium. Thus, MGd may allow differentia-
tion between fibrous caps and lipid cores under MRI. In
addition, we also determined a suitable dosage (0.004
mmol/kg) of MGd for near-optimal internalization and
enhancement of the vascular cells.
Surface coil–based MRI generated during this study
demonstrate a potential for MGd to discriminate be-
tween atherosclerotic plaque components, which can
be further enhanced by using the intravascular MRI
technique for better plaque characterization in the
deep-seated vessels. In addition, MRI showed that MGd
enhancement of the target vessel wall increased slowly
over at least a three-hour period. This may be reflective
of the slow cellular uptake of MGd by the vascular cells.
These results are particularly encouraging, suggesting
that MGd is steadily accumulating in the vessel wall
and being retained in the vascular cells over time. These
manifestations further support that MGd may function
as a useful MR contrast agent for plaque characteriza-
tion of deep-seated vessels using high-resolution MR
vessel wall imaging.
Magnevist, a commonly used contrast agent with
well-documented effects, was used here as a control.
Magnevist is a small molecule that diffuses freely from
the bloodstream into the vascular wall. It remains in the
extracellular fluid and does not chemically target spe-
cific cell types. It is also cleared from the bloodstream
rapidly. In this study, Magnevist exhibited characteris-
tic behavior: reaching maximal enhancement very
quickly and then diminished as it was cleared from the
blood. The administered dose of MGd was 100-fold less
than that of Magnevist, which may explain the lack of
immediate enhancement of the vessel walls. The slow
build-up of enhancement is believed to be due to the
necessary time period for vascular cells to uptake and
internalize the agent. The limitation of this study is that
it was unclear whether MGd enhancement continued to
increase beyond this point of three-hours postinjection.
A longer time period after injection would be needed to
fully determine the enhancement behavior.
MGd is a texaphyrin molecule that covalently binds
the paramagnetic metal gadolinium. Texaphyrins have
several useful qualities. They accumulate in highly
metabolic tissues, not only tumors but also plaques as
demonstrated in this study. Some texaphyrins function
as radiation enhancers, photosensitizers, or chemo-
therapy enhancers. In the present study, we demon-
strated the added benefit of MGd in functioning as a T1
MR contrast agent. This function is due to the bound
gadolinium ion within the MGd molecule. In addition,
texaphyrins are fully aromatic with a dark green color
and emit fluorescent light when excited by a laser. This
allows for accurate molecular optical imaging. Appar-
ently, the further combination of the two MGd func-
tions, therapy and imaging, should enable us to open
new avenues, using MGd-enhanced MRI technology to
simultaneously diagnose atherosclerotic plaques and
guide interventional therapies of atherosclerotic cardio-
vascular disease.
The limitation of this study is that the initial nominal
concentration of MGd for our in vivo experiments was
calculated assuming distribution in blood plasma only.
Its actual free concentration may depend on binding
with albumin, lipoproteins, and blood cells. Further-
more it is possible that MGd is able to diffuse through
the vascular wall into the interstitium and some
amount of MGd is cleared by the kidneys and liver over
two to three hours of experiments. These factors war-
rant further studies to understand the working mech-
anisms of MGd as an intracellular MR contrast agent.
In conclusion, the present study provides initial evi-
dence that MGd can generate contrast between various
vascular tissue types, such as fibrous tissues involved
in atherosclerotic plaques, and may be useful for
plaque characterization of deep-seated arteries using
high-resolution, contrast-enhanced MR vessel wall im-
aging.
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